Oral Vaccine Delivery: Can it Protect Against Non-mucosal Pathogens?

Lina Wang; Ross L Coppel

Disclosures

Expert Rev Vaccines. 2008;7(6):729-738. 

In This Article

Five-year View

In the past few years, there has been a major increase in interest in developing orally delivered vaccines and this trend will continue in the coming years. However, a subunit-based oral vaccine will almost certainly not be commercially available in the next 5 years, although we may see one or a few whole organism-based oral vaccines that are now in late clinical trials reaching the market. It is reasonable to speculate that oral vaccines against mucosal pathogens will arrive on the market sooner, owing to their advanced development and their relevance to mucosal immunity. For malaria prevention, given the complexity of this disease and the requirement for broad immune responses to multiple antigens, vaccine development has been challenging and tedious, and no licensed vaccine is currently available nor likely to be so in the next 5 years.[31,32] The priority for future development will be a safe and efficient vaccine of any type, which is more likely to be an injectable vaccine due to their greater efficacy. However, experience and lessons learned from the development process of injectable vaccines, as well as those from oral vaccines, would shorten the development time for a new generation of malaria vaccines.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....